By VFC’s Stock House
Mannkind Corporation (NASDAQ:MNKD) announced yesterday evening that its previously cancelled meeting with the FDA has been rescheduled.
The meeting was originally cancelled last week due to a looming government shutdown, but a last-minute deal in Washington prevented an actual shutdown and the FDA quickly responded (about the only thing that organization does quickly) and rescheduled the date for May 4th.
The quick rescheduling is a positive development for Mannkind and alleviates any fears that may have existed of the FDA giving the company the cold shoulder.
Little changes, however, in the fact that Mannkind will need to conduct an additional trial before once again seeking approval — rescheduled meeting or not.
The short term potential lies in the possibility of a partnership being announced.
Long term, MNKD could still pay off pretty big if Afrezza is ultimately approved.
Disclosure: Long MNKD call options
VFC’s Stock House offers investing opinions, insight and ideas on a variety of different stocks, options and ETF’s, as well as commenting on news that effects the market.
To discuss this article or any stock, please visit The Playground Discussion Forum!
